解决多发性骨髓瘤双特异性抗体治疗的实际挑战
Sreeraj Vasudevan1, Bhavesh Mohan Lal2, Nikhil Vojjala3
1Department of Hematology, Amala Institute of Medical Sciences, Thrissur, India.
Expert opinion on biological therapy
|April 18, 2025
概括
双特异性抗体 (bsAbs) 在多发性髓瘤中表现有前途. 专家意见指导最佳使用,毒性管理和与其他疗法进行测序,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 双特异性抗体 (bsAbs) 在复发性/耐药性多发性髓瘤中有效.
- 调查研究在早期骨髓瘤阶段探索bsAbs,包括新诊断的患者.
研究的目的:
- 为了解决有关bsAb选择和管理的关键临床问题.
- 讨论BSAb相关毒性和疾病复发的管理策略.
主要方法:
- 审查目前的临床实践和关于bsAb治疗的专家意见.
- 讨论关于毒性管理 (例如,托西利祖马布,类固醇) 和感染风险减轻的新出现的数据.
- 探索治疗疾病复发的策略,并使用CAR T细胞疗法对bsAbs进行测序.
主要成果:
- 托西利祖马布和类固醇正在研究细胞因子释放综合征 (CRS) 和神经毒性.
- 感染仍然是一个风险,需要修改剂量或有限治疗持续时间等策略.
- 用CAR T细胞疗法进行复发和测序的最佳管理需要进一步的研究.
结论:
- 需要进一步的研究,以获得最佳的bsAb选择,剂量和毒性管理.
- 在bsAb治疗后管理感染和疾病复发的策略至关重要.
- 对bsAbs与仿真抗原受体 (CAR) T细胞疗法的测序需要澄清.
相关概念视频
01:31Hybridoma Technology
14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K